Literature DB >> 22926856

Glucose metabolism and pancreatic defects in spinal muscular atrophy.

Melissa Bowerman1, Kathryn J Swoboda, John-Paul Michalski, Gen-Sheng Wang, Courtney Reeks, Ariane Beauvais, Kelley Murphy, John Woulfe, Robert A Screaton, Fraser W Scott, Rashmi Kothary.   

Abstract

OBJECTIVE: Spinal muscular atrophy (SMA) is the number 1 genetic killer of young children. It is caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. Although SMA is primarily a motor neuron disease, metabolism abnormalities such as metabolic acidosis, abnormal fatty acid metabolism, hyperlipidemia, and hyperglycemia have been reported in SMA patients. We thus initiated an in-depth analysis of glucose metabolism in SMA.
METHODS: Glucose metabolism and pancreas development were investigated in the Smn(2B/-) intermediate SMA mouse model and type I SMA patients.
RESULTS: Here, we demonstrate in an SMA mouse model a dramatic cell fate imbalance within pancreatic islets, with a predominance of glucagon-producing α cells at the expense of insulin-producing β cells. These SMA mice display fasting hyperglycemia, hyperglucagonemia, and glucose resistance. We demonstrate similar abnormalities in pancreatic islets from deceased children with the severe infantile form of SMA in association with supportive evidence of glucose intolerance in at least a subset of such children.
INTERPRETATION: Our results indicate that defects in glucose metabolism may play an important contributory role in SMA pathogenesis.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926856      PMCID: PMC4334584          DOI: 10.1002/ana.23582

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

Review 1.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

Review 2.  The neurobiology of childhood spinal muscular atrophy.

Authors:  T O Crawford; C A Pardo
Journal:  Neurobiol Dis       Date:  1996-04       Impact factor: 5.996

3.  Familial adult-onset proximal spinal muscular atrophy. Report of a family with type II hyperlipoproteinemia.

Authors:  S H Quarfordt; D C DeVivo; W K Engel; R I Levy; D S Fredrickson
Journal:  Arch Neurol       Date:  1970-06

Review 4.  Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.

Authors:  Michael B Ranke
Journal:  Trends Endocrinol Metab       Date:  2005 May-Jun       Impact factor: 12.015

5.  Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.

Authors:  G Di Cola; M H Cool; D Accili
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

6.  Does diabetes mellitus target motor neurons?

Authors:  Noor Ramji; Cory Toth; James Kennedy; Douglas W Zochodne
Journal:  Neurobiol Dis       Date:  2006-12-29       Impact factor: 5.996

7.  Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes.

Authors:  Bangyan L Stiles; Christine Kuralwalla-Martinez; Wei Guo; Caroline Gregorian; Ying Wang; Jide Tian; Mark A Magnuson; Hong Wu
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

8.  Hyperinsulinism and neuromuscular disorders; a consideration of the association of pancreatic adenoma with wasting states.

Authors:  R W BARRIS
Journal:  Calif Med       Date:  1953-03

9.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

Authors:  Amy M Avila; Barrington G Burnett; Addis A Taye; Francesca Gabanella; Melanie A Knight; Parvana Hartenstein; Ziga Cizman; Nicholas A Di Prospero; Livio Pellizzoni; Kenneth H Fischbeck; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

10.  Insulin and glucagon regulate pancreatic α-cell proliferation.

Authors:  Zhuo Liu; Wook Kim; Zhike Chen; Yu-Kyong Shin; Olga D Carlson; Jennifer L Fiori; Li Xin; Joshua K Napora; Ryan Short; Juliana O Odetunde; Qizong Lao; Josephine M Egan
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

View more
  63 in total

1.  The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.

Authors:  Matthew E R Butchbach; Jasbir Singh; Mark E Gurney; Arthur H M Burghes
Journal:  Exp Neurol       Date:  2014-03-25       Impact factor: 5.330

Review 2.  Disease mechanisms and therapeutic approaches in spinal muscular atrophy.

Authors:  Sarah Tisdale; Livio Pellizzoni
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

3.  SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy.

Authors:  Marie-Therese Khairallah; Jacob Astroski; Sarah K Custer; Elliot J Androphy; Craig L Franklin; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

Review 4.  Diverse role of survival motor neuron protein.

Authors:  Ravindra N Singh; Matthew D Howell; Eric W Ottesen; Natalia N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-15       Impact factor: 4.490

Review 5.  Spinal muscular atrophy: diagnosis and management in a new therapeutic era.

Authors:  W David Arnold; Darine Kassar; John T Kissel
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

Review 6.  Advances in modeling and treating spinal muscular atrophy.

Authors:  Meaghan Van Alstyne; Livio Pellizzoni
Journal:  Curr Opin Neurol       Date:  2016-10       Impact factor: 5.710

Review 7.  How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.

Authors:  N N Singh; M D Howell; E J Androphy; R N Singh
Journal:  Gene Ther       Date:  2017-05-09       Impact factor: 5.250

Review 8.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

9.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Authors:  Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

Review 10.  Spinal muscular atrophy: journeying from bench to bedside.

Authors:  Tomoyuki Awano; Jeong-Ki Kim; Umrao R Monani
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.